Clinical Trial Update: Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating vortioxetine for major depressive disorder with co-morbid conditions following traumatic brain injury has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Traumatic Brain Injury

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Johns Hopkins University | Conditions: TBI, Major Depression | Phase 3 | Status: WITHDRAWN